Company intelligence / Profile preview

Manitari Pharma

Toronto, Canada

Ownership: Private
Development stage: Other

Overview

Manitari Pharma holds a Health Canada Dealer’s License to process psilocybin and psilocin for research and product supply; it is focusing on R&D and supply infrastructure for psychedelic-assisted therapy targeting mental health conditions, especially in Indigenous and First Nations populations[1][3][5][7].

Therapeutic areas: Psychiatry
Modalities: Small moleculeNatural product (psilocybin, psilocin)
Industry: Biotech

Partnerships

Optimind Pharma (joint venture, previously 40% interest; stake relinquished in 2025)[1][3][9]Mohawk community in Quebec (collaborative licensing and R&D agreement)[7]

Beyond the preview

Go deeper on Manitari Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Manitari Pharma.

Explore the full profile